# Assembly Biosciences to Present Topline Phase 1a Data on Hepatitis Delta Virus Entry Inhibitor ABI-6250 at the EASL Congress 2026
Canonical URL: https://biopharmsignal.com/news/ASMB/assembly-biosciences-to-present-topline-phase-1a-data-on-hepatitis-delta-virus-entry-inhibitor-abi-6250-at-the-easl-congress-2026
Ticker: ASMB
Company: Assembly Biosciences
Source: Assembly Biosciences
Published: 2026-05-13 06:00 EST
Original Source URL: https://investor.assemblybio.com
## Summary

SOUTH SAN FRANCISCO, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced topline clinical data on ABI-6250, an investigational oral hepatitis D virus (HDV)

## Article Body
SOUTH SAN FRANCISCO, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced topline clinical data on ABI-6250, an investigational oral hepatitis D virus (HDV)
## Recent Company News
- 2026-05-28 20:05 EST — [Assembly Biosciences Announces Upcoming Investor Conference Presentations](https://biopharmsignal.com/news/ASMB/assembly-biosciences-announces-upcoming-investor-conference-presentations) — Source: Assembly Biosciences
- 2026-05-26 20:05 EST — [Assembly Biosciences Announces the Closing of its Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters’ Option to Purchase Additional Shares](https://biopharmsignal.com/news/ASMB/assembly-biosciences-announces-the-closing-of-its-offering-of-common-stock-and-pre-funded-warrants-and-full-exercise-of-the-underwriters-option-to-purchase-additional-shares) — Source: Assembly Biosciences
- 2026-05-22 11:05 EST — [Assembly Biosciences Announces Pricing of $100 Million Offering of Common Stock and Pre-Funded Warrants](https://biopharmsignal.com/news/ASMB/assembly-biosciences-announces-pricing-of-100-million-offering-of-common-stock-and-pre-funded-warrants) — Source: Assembly Biosciences
- 2026-05-22 11:00 EST — [Assembly Biosciences Announces Expansion of ABI-6250 Clinical Development Into Cholestatic Liver Diseases](https://biopharmsignal.com/news/ASMB/assembly-biosciences-announces-expansion-of-abi-6250-clinical-development-into-cholestatic-liver-diseases) — Source: Assembly Biosciences
- 2026-05-13 06:00 EST — [Assembly Biosciences to Present Topline Phase 1a Data on Hepatitis Delta Virus Entry Inhibitor ABI-6250 at the EASL Congress 2026](https://biopharmsignal.com/news/ASMB/assembly-biosciences-to-present-topline-phase-1a-data-on-hepatitis-delta-virus-entry-inhibitor-abi-6250-at-the-easl-congress-2026) — Source: Assembly Biosciences
## Related News
- 2026-07-22 20:05 EST — VKTX — [Viking Therapeutics to Report Financial Results for Second Quarter 2026 on July 29, 2026](https://biopharmsignal.com/news/VKTX/viking-therapeutics-to-report-financial-results-for-second-quarter-2026-on-july--bbf2553f)
- 2026-07-22 20:01 EST — AXON — [Axon to Release Second Quarter 2026 Earnings on August 5, 2026](https://biopharmsignal.com/news/AXON/axon-to-release-second-quarter-2026-earnings-on-august-5-2026-66120902)
- 2026-07-22 12:39 EST — ARTL — [New Analysis of Over 50 Studies Showed that All the Non-Prescription CBD Products Researched Fell Short of Therapeutic Efficacy — Reinforcing the Case for Artelo's Optimized ART12.11 CBD Composition](https://biopharmsignal.com/news/ARTL/new-analysis-of-over-50-studies-showed-that-all-the-non-prescription-cbd-product-a3445432)
- 2026-07-22 12:30 EST — NRSN — [NeuroSense Advances PrimeC Toward New Drug Submission to Health Canada for ALS](https://biopharmsignal.com/news/NRSN/neurosense-advances-primec-toward-new-drug-submission-to-health-canada-for-als-721c198c)
- 2026-07-22 12:30 EST — PRGO — [Perrigo to Release Second Quarter 2026 Financial Results on August 5, 2026](https://biopharmsignal.com/news/PRGO/perrigo-to-release-second-quarter-2026-financial-results-on-august-5-2026-ff2ea2a5)